Skip to main content

Month: August 2025

APWC Announces Financial Results for the Second Quarter of 2025

Quarterly revenue of $126.9 million, up 26% from Q1 and up 11% from a year ago Quarterly EPS was $0.03, up 143% from Q1 and 250% from a year agoTAIPEI, Taiwan, Aug. 14, 2025 (GLOBE NEWSWIRE) — Asia Pacific Wire & Cable Corporation Limited (“APWC” or the “Company”) (NASDAQ: APWC) today reported unaudited results for the second quarter ended June 30, 2025. Quarterly revenue was $126.9 million, up 26% from the previous quarter and up 11% from a year ago. Copper unit volume, measured by the tonnage of copper contained in the wire and cable sold, increased by 13% in the second quarter but decreased by 9% from a year ago. This does not include other raw materials, such as aluminum and insulation materials. For the quarter, earnings per share were $0.03, up 143% from the previous quarter and up 250% from...

Continue reading

Lifeward Ltd. Reports Second Quarter 2025 Financial Results

Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) —  Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments for LifewardAchieved FDA clearance and subsequent U.S. launch in April 2025 for the ReWalk 7, the latest innovation in the ReWalk pipeline, with over 20 ReWalk 7 units...

Continue reading

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use

10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancer H. pylori linked to approximately 80% of gastric cancer cases; classified as a Class 1 carcinogen by the World Health Organization Gastric cancer ranks as the fifth most common cancer globally and the fourth leading cause of cancer-related deathsIRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, today announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved Biomerica’s Fortel® Ulcer Test for home use. This marks a milestone in expanding access to accurate, easy-to-use diagnostic tools for one of the leading causes of gastric disease in the region. The Fortel® Ulcer Test is a 10-minute...

Continue reading

Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY) (“Biotricity” or the “Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “We’re proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, exemplifying our ability to grow our business as we go from a loss-producing startup to a business that can operate...

Continue reading

Nuwellis, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company dedicated to transforming care for fluid overload patients, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic realignment during the second quarter, sharpening focus on high-impact growth areas in pediatric and cardiac surgery care while laying the foundation for expansion in outpatient heart failure. Despite temporary revenue disruption related to an industry-wide sterilization vendor issue, the company took swift action to prioritize patient care, protect its most vulnerable populations, and ensure strong momentum entering the third quarter.Revenue of...

Continue reading

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) Received FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for CAN-2409 for the treatment of prostate cancer Preparations on track for Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer, with submission expected in Q4 2026 Received Orphan Designation for CAN-2409 for the treatment of pancreatic cancer from the European Medicines Agency (EMA) Cash and cash equivalents of $100.7 million, as of June 30, 2025, will be sufficient to fund operations into Q1 2027NEEDHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) —...

Continue reading

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in Europe ONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United StatesISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the third quarter of fiscal year 2025 and provided a corporate update. Financial Highlights for the Fiscal Third Quarter Ended June 30, 2025 For the fiscal third quarter ended June 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of $20.2 million, or $0.55 per basic and diluted share, and $1.5 million of revenue. Revenue consisted...

Continue reading

IDEX Biometrics ASA: Extraordinary general meeting held on 14 August 2025

IDEX Biometrics ASA held an extraordinary general meeting on 14 August 2025.All resolutions were passed as proposed in the notice and agenda update for the meeting.The minutes of the meeting will be available at the company’s web site in due course. IDEX Biometrics’ reports and presentations are available on our website: www.idexbiometrics.com/investors For further information, please contact: Anders Storbråten, CEO and CFO, Tel: +47 416 38 582 E-mail: ir@idexbiometrics.com About IDEX Biometrics: IDEX Biometrics ASA (IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated...

Continue reading

Edible Garden Delivers Strong Performance Across Core and Key Segments, Driven by Strategic Portfolio Transformation

 Company exits low-margin product lines, invests in higher-margin, innovative CEA-informed, better-for-you shelf-stable products, and expands global reach Conference Call to Be Held Today at 8:00 am ET. BELVIDERE, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, better-for-you, sustainable produce and products, today reported strong core business performance for the three months ended June 30, 2025, and shared a strategic business update. This performance reflects the Company’s disciplined portfolio optimization strategy following a recent acquisition, which involved eliminating underperforming, low-margin product lines and making targeted investments in higher-margin, innovative,...

Continue reading

OneMedNet Reports 80% Reduction in Debt Enabling Focus On Growth

MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced its financial results for the second quarter ended June 30, 2025, including its significantly improved balance sheet. Second Quarter and First Half 2025 Financial HighlightsImproved Balance Sheet: Due to the combination of debt conversions, vendor repayments, and highly discounted debt settlements, total liabilities have been reduced from $19.7 million as of December 31, 2024, to $6.2 million as of June 30, 2025, a reduction of approximately $13.5 million. Additional discounted debt settlements in July 2025 further reduced liabilities by $1.9 million, resulting in aggregate reductions in liabilities by approximately 80% since December 31, 2024.   Net...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.